CD64 CAR T cells

CD64 CAR T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD64 (FcγRI), a high-affinity IgG receptor that is constitutively expressed on certain subtypes of acute myeloid leukemia (AML), specifically acute myelomonocytic (M4) and acute monocytic (M5) leukemia. The CAR construct typically utilizes a humanized CD64-specific single-chain variable fragment (scFv, such as clone H-22) coupled with 4-1BB and CD3ζ signaling domains. To address challenges such as poor persistence and expansion in the AML microenvironment, researchers have engineered these cells to overexpress Interleukin-15 (IL-15). This modification promotes a central memory phenotype, reduces T-cell exhaustion, and enhances anti-leukemic efficacy. Developed by institutions including the Chinese Academy of Medical Sciences and Peking Union Medical College, CD64 CAR T cells represent a targeted approach to treating relapsed or refractory AML while potentially sparing normal hematopoietic stem cells.

Other names

CD64-targeted CAR T cellsCD-64-targeted CAR T cellsCD 64-targeted CAR T cellsFcγRI CAR T cellsCD64-targeted chimeric antigen receptor T cellsCD-64-targeted chimeric antigen receptor T cellsCD 64-targeted chimeric antigen receptor T cells